RT Journal Article
T1 Carbosilane dendrimers as carriers of siRNA
A1 Jiménez, José Luis
A1 Gómez, Rafael
A1 Briz, Veronica
A1 Madrid González, Ricardo
A1 Bryszewsk, Maria
A1 Mata, Francisco .Javier. de la
A1 Muñoz-Fernández, María Ángeles
AB Despite the enormous possibilities of RNAi, there still exist many problems that need to be addressed. Obstacles in delivery, target cell transfection, stability/degradation, transient activity, secondary effects, toxicity caused by the delivery vector, and resistance all hinder the path of carrying out in vivo experiments with RNAi and further developing RNAi as a new therapy for clinical use. Notwithstanding, the majority of research that uses RNAi depends on a delivery vector of some kind. This review offers a brief overview of the current status of carbosilane dendrimers as siRNA delivery vectors.
PB Elsevier
SN 1773-2247
YR 2012
FD 2012
LK https://hdl.handle.net/20.500.14352/99626
UL https://hdl.handle.net/20.500.14352/99626
LA eng
NO Jiménez, J. L., et al. «Carbosilane Dendrimers as Carriers of siRNA». Journal of Drug Delivery Science and Technology, vol. 22, n.o 1, 2012, pp. 75-82. https://doi.org/10.1016/S1773-2247(12)50007-9.
NO AcknowledgementsSources of financial support: Grants from MNT-ERA NET transnational call 2007; COST Action (TD0802), Red RIS RD06-0006-0035, Fondo de Investigación Sanitaria (PI09/02029; PI080222; PI081495), Fundación para la Investigación y la Prevención del SIDA en España (FIPSE 240800/09), EuroEraNet DENPEPTHIV PS09/02669, DENANORNA, and CIBER-BBN del Instituto de Salud Carlos III. JLJF is supported by Programa de Investigación de la Consejería de Sanidad de la Comunidad de Madrid.
NO Fundación para la Investigación y la Prevención del SIDA en España
NO Instituto de Salud Carlos III
NO Comunidad de Madrid
DS Docta Complutense
RD 22 abr 2025